NCT04036292 - Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease | Biotech Hunter

Enrollment

758

Participants

Timeline

Start Date

July 23, 2019

Primary Completion Date

April 10, 2020

Study Completion Date

February 5, 2021

Conditions

Dry Eye Disease (DED)

Interventions

DRUG

OC-01 (varenicline) nasal spray

DRUG

Placebo (vehicle) nasal spray

Trial Locations (22)

16066

Cranberry Township, Cranberry Township

24502

Lynchburg, Lynchburg

27603

Raleigh, Raleigh

28150

Shelby, Shelby

33484

Delray Beach, Delray Beach

37210

Nashville, Nashville

40206

Louisville, Louisville

46290

Indianapolis, Indianapolis

57108

Sioux Falls, Sioux Falls

58103

Fargo, Fargo

77025

Houston, Houston

78209

San Antonio, San Antonio

78229

San Antonio, San Antonio

78731

Austin, Austin

80528

Fort Collins, Fort Collins

84041

Layton, Layton

85032

Phoenix, Phoenix

89052

Las Vegas, Las Vegas

92663

New Port Beach, Newport Beach

06708

Waterbury, Waterbury

02767

Raynham, Raynham

02842

Warwick, Warwick